ArticlePloS one2025
The rising burden of female cancer in Ethiopia (2000-2021) and projections to 2040: Insights from the global burden of disease study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ovarian Cancer Mortality Predictors in Public Oncology Centers, Addis Ababa, Ethiopia: A Case-Control Study.Cancer reports (Hoboken, N.J.) · 2026Article
- Global Patterns and Temporal Trends in Ovarian and Uterine Cancer Mortality Attributable to High Body-Mass Index, 1990-2023.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFemale cancers-breast, cervical, ovarian, and uterine-pose significant public health and socio-economic challenges, particularly in low- and middle-income countries like Ethiopia. However, detailed and geographically disaggregated data are limited, hindering effective policymaking. To address this gap, our study utilizes the Global Burden of Disease (GBD) methodology to analyze 21 years (2000-2021) of national and sub-national trends and risk factors for these cancers in Ethiopia, with projections to 2040, to support targeted cancer control and health system strengthening.
methodsUsing the 2021GBD data, we analyzed the national and sub-national prevalence, incidence, mortality, disability-adjusted life years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) for female specific cancer in Ethiopia. An Autoregressive Integrated Moving Average (ARIMA) model was employed for projecting epidemiological trajectories through 2040. All statistical analyses and data visualization were performed using Python.
resultsIn 2021, the Ethiopian incidence of female breast, cervical, ovarian, and uterine cancer was 7,308 (95% uncertainty interval (UI): 5,794-9,199), 7,884 (95% UI: 5,759-11,765), 2,054 (95% UI: 1,034-2,929), and 669 (95% UI: 422-1,126), respectively. Cervical cancer accounts for the highest number of DALYs, 162,776 (95% UI: 119,900-239,116), followed by breast, ovarian, and uterine cancer at 155,931 (95% UI: 123,015-196,249), 40,430 (95% UI: 19,885-57,414), and 8,882 (95% UI: 5,579-15,240), respectively. Projections to 2040 indicate a continued rise in incidence for all female cancers.
conclusionsBreast and ovarian cancers are emerging public health crises in Ethiopia, with significant increases in prevalence, incidence, and DALYs. While the cervical cancer burden is declining, rising YLDs indicate a growing need for long-term care. The projected rise in female cancer incidence calls for urgent, targeted interventions focused on early diagnosis, age-appropriate screening, and improved cancer care services to reduce the adverse impact on Ethiopian women's health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.